Association between Immunohistochemical Expression of Topoisomerase IIα,Her2 and Hormone Receptors and Response to Primary Chemotherapy in Breast Cancer
Restricted accessResearch articleFirst published online May, 2006
Association between Immunohistochemical Expression of Topoisomerase IIα,Her2 and Hormone Receptors and Response to Primary Chemotherapy in Breast Cancer
The aim of this study was to evaluate the association between immunohistochemical expression of topoisomerase IIα, HER2 and hormone receptors and response to primary anthracycline-based chemotherapy in locally advanced breast cancer. We analyzed 109 medical charts of patients treated with primary anthracycline-based chemotherapy in the Women's Integral Health Care Center from 1996 to 2004. The clinical and pathological response to primary chemotherapy was associated with topoisomerase IIα and HER2 expression and hormone receptor negativity. Statistical analysis was performed using chi-squared, Fisher's exact test and Mann-Whitney test. No statistical association between clinical response and expression of topoisomerase IIa, HER2 and hormone receptor negativity was found. However, there was an association between complete pathological response and hormone receptor negativity (P = 0.0289). The present study suggested that these markers should not be considered predictors of response to primary anthracycline-based chemotherapy, and prospective studies must be designed for this purpose.
KaufmannM., Von MinchwitzG., SmithR., ValeroV., GianniL., EiermannW., HowellA., CostaS.D., BeuzebocP., UntchM., BlohmerJ.U., SinnH.P., SittekR., SouchonR., TulusanA.H., VolmT., SennH.J.: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.J Clin Oncol, 21: 2600–2608, 2003.
2.
ValeroV.V., BuzdarA.U., HortobagyiG.N.: Locally advanced breast cancer.Oncologist, 1: 8–17, 1996.
3.
ManoM.S., AwadaA.: Primary chemotherapy for breast cancer: the evidence and the future.Ann Oncol, 15: 1161–1171, 2004.
4.
CholletP., AmatS., CureH., de LatourM., Le BouedecG., Mouret-ReynierM.A., FerriereJ.P., AchardJ.L., DauplatJ., Penault-LlorcaF.: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer.Br J Cancer, 86: 1041–1046, 2002.
5.
Van Der HageJ.A., Van De VeldeCjh, JulienJ.P., Tubiana-HulinM., VanderveldenC., DuchateauL.: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902.J Clin Oncol, 19: 4224–4237, 2001.
6.
BonadonnaG., ValagussaP., BrambillaC., FerrariL., MoliterniA., TerenzianiM., ZambettiM.: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.J Clin Oncol, 16: 93–100, 1998.
7.
SchollS.M., FourquetA., AsselainB., PiergaJ.Y., VilcoqJ.R., DurandJ.C., DorvalT., PalangieT., JouveM., BeuzebocP.: Primary versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomized trial.Eur J Cancer,30A: 645–652, 1994.
8.
WangJ.C.: DNA Topoisomerases.Ann Rev Biochem, 65: 635–692, 1996.
9.
KellnerU., SehestedM., JensenP.B., GieselerF., RudolphP.: Culprit and victim – DNA topoisomerase II.Lancet Oncol, 3: 235–243, 2002.
10.
JärvinenT.A.H., TannerM., RantanenV., BarlundM., BorgA., GrenmanS., IsolaJ.: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.Am J Pathol, 156: 839–847, 2000.
11.
ZhouZ., ZwellingL.A., KawakamiY., AnT., KobayashiK., HerzogC., KleinermanE.S.: Adenovirus-mediated human topoisomerase IIa gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.Cancer Res,59: 4618–4624, 1999.
12.
NitissJ.L., BeckW.T.: Antitopoisomerase drug action and resistance.Eur J Cancer,32A: 958–966, 1996.
13.
WithoffS., KeithW.N., KnolA.J., CouttsJ.C., HoareS.F., MulderN.H., de VriesE.G.: Selection of a subpopulation with fewer DNA topoisomerase IIα gene copies in a doxorubicin-resistant cell panel.Br J Cancer, 74: 502–507, 1996.
14.
GudkovA.V., ZelnickC.R., KazarovA.R., ThimmapayaR., SuttleD.P., BeckW.T., RoninsonI.B.: Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.Proc Natl Acad Sci USA, 90: 3231–3235, 1993.
15.
SmithK., HoulbrookS., GreenallM., CarmichaelJ., HarrisA.L.: Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.Oncogene, 8: 933–938, 1993.
16.
JärvinenT.A.H., KononenJ., Pelto-HuikkoM., IsolaJ.: Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erbB-2 overexpression in breast cancer.Am J Pathol, 148: 2073–2082, 1996.
17.
YamauchiH., StearnsV., HayesD.F.: When is a tumor marker ready for prime time?A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol, 19: 2334–2356, 2001.
18.
JärvinenT.A.H., TannerM., BarlundM., BorgA., IsolaJ.: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.Genes Chromosomes Cancer, 26: 142–150, 1999.
19.
JärvinenT.A.H., LiuE.T.: HER2-neu and topoisomerase II alpha in breast cancer.Breast Cancer Res Treat, 78: 299–311, 2003.
20.
MussH.B., ThorA.D., BerryD.A., KuteT., LiuE.T., KoernerF., CirrincioneC.T., BudmanD.R., WoodW.C., BarcosM.: C-erbB.2 expression and response to adjuvant therapy in women with node-positive early breast cancer.N Engl J Med, 330: 1260–1266, 1994.
21.
PaikS., BryantJ., ParkC., FisherB., Tan-ChiuE., HyamsD., FisherE.R., LippmanM.E., WickerhamD.L., WolmarkN.: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.J Natl Cancer Inst, 90: 1361–1370, 1998.
22.
JärvinenT.A.H., HolliK., KuukasjärviT., IsolaJ.J.: Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.Br J Cancer, 77: 2267–2273, 1998.
23.
Martin-RichardM., MuñozM., AlbanellJ., ColomoL., BelletM., ReyM.J., TaberneroJ., AlonsoC., CardesaA., GasconP., FernandezP.L.: Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant antracycline-based chemotherapy.Oncology, 66: 388–394, 2004.
24.
CardosoF., DurbecqV., LarsimontD., PaesmansM., LeroyJ.Y., RouasG., SotiriouC., RenardN., RichardV., PiccartM.J., Di LeoA.: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase IIα gene amplification and protein overexpression in locally advanced/metastatic breast cancer.Int J Oncol, 24: 201–209, 2004.
PetitT., WiltM., VeltenM., MillonR., RodierJ.F., BorelC., MorsR., HaegeleP., EberM., GhnassiaJ.P.: Comparative value of tumour grade, hormonal receptors, Ki-67, HER2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.Eur J Cancer, 40: 205–211, 2004.
27.
ColleoniM., VialeG., ZahriehD., PruneriG., GentiliniO., VeronesiP., GelberR.D., CuriglianoG., TorrisiR., LuiniA., IntraM., GalimbertiV., RenneG., NoleF., PeruzzottiG., GoldhirschA.: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment.Clin Cancer Res, 10: 6622–6628, 2004.
28.
FisherB., BryantJ., WolmarkN., MamounasE., BrownA., FisherE.R., WickerhamD.L., BegovicM., DeCillisA., RobidouxA., MargoleseR.G., CruzABJr., HoehnJ.L., LeesA.W., DimitrovN.V., BearH.D.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol, 16: 2672–2685, 1998.
29.
KuererH.M., NewmanL.A., SmithT.L., AmesF.C., HuntK.K., DhingraK., TheriaultR.L., SinghG., BinkleyS.M., SneigeN., BuchholzT.A., RossM.I., McNeeseM.D., BuzdarA.U., HortobagyiG.N., SingletaryS.E.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.J Clin Oncol, 17: 460–457, 1999.
30.
PiergaJ.Y., MouretE., DierasV., LaurenceV., BeuzebocP., DorvalT., PalangieT., JouveM., Vincent-SalomonA., SchollS., ExtraJ.M., AsselainB., PouillartP.: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.Eur J Cancer, 83: 1480–1487, 2000.
31.
MastersJ.R.W., CamplejohnR.S., MillisR.R., RubensR.D.: Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer.Br J Cancer, 55: 455–457, 1987.
32.
ChangJ., OmerodM., PowlesT.J., AllredD.C., AshleyS.E., DowsettM.: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.Cancer (Phil), 89: 2145–2152, 2000.
33.
ColleoniM., MinchellaI., MazzarolG., NoleF., PeruzzottiG., RoccaA., VialeG., OrlandoL., FerrettiG., CuriglianoG., VeronesiP., IntraM., GoldhirschA.: Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.Ann Oncol,11: 1057–1059, 2000.
34.
BonnefoiH., Diebold-BergerS., TherasseP., HamiltonA., van de VijverM., MacGroganG., ShepherdL., AmaralN., DuvalC., DrijkoningenR., LarsimontD., PiccartM.: Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?Ann Oncol, 14: 406–413, 2003.
35.
AasT., GeislerS., EideG.E., HaugenD.F., VarhaugJ.E., BassoeA.M., ThorsenT., BerntsenH., Borresen-DaleA.L., AkslenL.A., LonningP.E.: Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.Eur J Cancer, 39: 438–446, 2003.
36.
AnelliA., BrentaniR.R., GadelhaA.P., Amorim De AlbuquerqueA., SoaresF.: Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer.Ann Oncol, 14: 428–432, 2003.
37.
AyersM., SymmansW.P., StecJ., DamokoshA.I., ClarkE., HessK., LecockeM., MetivierJ., BooserD., IbrahimN., ValeroV., RoyceM., ArunB., WhitmanG., RossJ., SneigeN., HortobagyiG.N., PusztaiL.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.J Clin Oncol, 22: 2284–2293, 2004.
TherasseP., ArbuckS.G., EisenhauerE.A., WandersJ., KaplanR.S., RubinsteinL., VerweijJ., Van GlabbekeM., van OosteromA.T., ChristianM.C., GwytherS.G.: New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst, 92: 205–216, 2000.
40.
SobinL.H., WittekindCh: TNM Classification of Malignant Tumours, 6 ed, pp 131–142, Wiley-Liss, New York, 2002.
41.
Associatión Médica Mundial.Declaração de Helsinki de la Associación Mundial. Princípios éticos para lãs investigaciones médicas em seres humanos (updated 2004 Oct 9) Available from: http://www.wma.net/s/policy/b3.htm
42.
Brasil. Resolução no 196/96 do Ministério da Saúde/Conselho Nacional de Saúde sobre pesquisa envolvendo seres humanos.Bioética,4: 15–25, 1996.
43.
GoldhirschA., GlickJ.H., GelberR.D., CoatesA.S., SennH.J.: Meeting highlights: International consensus panel on the treatment of primary breast cancer.Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol, 19: 3817–3827, 2001.
44.
JacobsT.W., GownA.M., YazijiH., BarnesM.J., SchnittS.J.: Specificity of HercepTest in determining HER2/neu status of breast cancers using the United States Food and Drug Administration – Approved Scoring System.J Clin Oncol, 17: 1983–1988, 1999.
45.
FisherL.D., Van BelleG.B.: Biostatistics: A Methodology for the Healthy Sciences, John Wiley, New York, 1991.
46.
ConoverW.J.: Practical Nonparametric Statistics, 3 ed, Wiley, New York, 1999.
47.
HellemansP., Van DamP.A., GeyskensM., van OosteromA.T., BuytaertP., Van MarckE.: Immunohistochemical study of topoisomerase IIα expression in primary ductal carcinoma of the breast.J Clin Pathol, 48: 147–150, 1995.
48.
RudolphP., MacGroganG., BonichonF., FrahmS.O., de MascarelI., TrojaniM., DurandM., AvrilA., CoindreJ.M., ParwareschR.: Prognostic significance of Ki-67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast.A multivariate analysis of 863 cases. Breast Cancer Res Treat, 55: 61–71, 1999.
49.
DepowskiP.L., RosenthalS.I., BrienT.P., StylosS., JohnsonR.L., RossJ.S.: Topoisomerase IIα expression in breast cancer: correlation with outcome variables.Mod Pathol, 13: 542–547, 2000.
50.
MacGroganG., RudolphP., Mascarel IdI., MauriacL., DurandM., AvrilA., DilhuydyJ.M., RobertJ., Mathoulin-PelissierS., PicotV., FloquetA., SierankowskiG., CoindreJ.M.: DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer.Br J Cancer, 89: 666–671, 2003.
51.
Di LeoA., LarsimontD., GancbergD., JarvinenT., BeauduinM., VindevoghelA., MichelJ., FocanC.H., RiesF., GobertP.H., Closon-DejardinM.T., DolciS., RouasG., PaesmansM., LobelleJ.P., IsolaJ., PiccartM.J.: HER2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.Ann Oncol, 12: 1081–1089, 2001.
52.
CoonJ.S., MarcusE., Gupta-BurtS., SeeligS., JacobsonK., ChenS., RentaV., FrondaG., PreislerH.D.: Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer.Clin Cancer Res, 8: 1061–1067, 2002.
53.
MuellerR.E., ParkesR.K., AndrulisI., O'MalleyF.P.: Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.Genes Chromosomes Cancer, 39: 288–297, 2004.
54.
DurbecqV., DesmedtC., PaesmansM., CardosoF., Di LeoA., ManoM., RouasG., LeroyJ.Y., SotiriouC., PiccartM., LarsimontD.: Correlation between topoisomerase-IIα gene amplification and protein expression in HER2 amplified breast cancer.Int J Oncol, 25: 1473–1479, 2004.
55.
BonfinA.M., YtterhusB., HagmarB.M.: TOP2a and HER2 gene amplification in fine needle aspirates from breast carcinomas.Cytopathology, 14: 314–319, 2003.
56.
KorenR., Rath-WolfsonL., RamE., ItzhacO.B., SchachterB., KleinB., GalR., DreznikZ.: Prognostic value of topoisomerase II in female breast cancer.Oncol Rep, 12: 915–919, 2004.
57.
ParkK., KimJ., LimS., HanS.: Topoisomerase IIα (TopoII) and HER2 amplification in breast cancer and response to preoperative doxorubicin chemotherapy.Eur J Cancer, 39: 631–634, 2003.
58.
Di LeoA., GancbergD., LarsimontD., TannerM., JarvinenT., RouasG., DolciS., LeroyJ.Y., PaesmansM., IsolaJ., PiccartM.J.: HER2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Clin Cancer Res, 8: 1107–1116, 2002.
59.
Vincent-SalomonA., CartonM., FreneauxP., PalangieT., BeuzebocP., MouretE., de CremouxP., CoueO., ZafraniB., NicolasA., CloughK., FourquetA., PouillartP., Sastre-GarauX.: ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy.Eur J Cancer, 36: 586–591, 2000.
60.
RozanS., Vincent-SalomonA., ZafraniB., ValidireP., De CremouxP., BernouxA., NieruchalskiM., FourquetA., CloughK., DierasV., PouillartP., Sastre-GarauX.: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer.Int J Cancer, 79: 27–33, 1998.
61.
Vargas-RoigL.M., GagoF.E., TelloO., Martin de CivettaM.T., CioccaD.R.: C-erbB-2 (HER-2/neu) protein and drug resistance cancer patients treated with induction chemotherapy.Int J Cancer, 84: 129–134, 1999.
62.
ZhangF., YangY., SmithT., KauS.W., McConathyJ.M., EstevaF.J., KuererH.M., SymmansW.F., BuzdarA.U., HortobagyiG.N., PusztaiL.: Correlation between HER2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.Cancer, 97: 1758–1765, 2003.
63.
StearnsV., SinghB., TsangarisT., CrawfordJ.G., NovielliA., EllisM.J., IsaacsC., PennanenM., TiberyC., FarhadA., SlackR., HayesD.F.: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.Clin Cancer Res, 9: 124–133, 2003.
64.
OgstonK.N., MillerI.D., SchofieldA.C., SpyrantisA., PavlidouE., SarkarT.K., HutcheonA.W., PayneS., HeysS.D.: Can patients likely to benefit from primary chemotherapy for breast cancer be predicted before commencement of treatment?Breast Cancer Res Treat, 86: 181–189, 2004.
65.
FisherB., BrownA., MamounasE., WieandS., RobidouxA., MargoleseR.G., CruzABJr., FisherE.R., WickerhamD.L., WolmarkN., DeCillisA., HoehnJ.L., LeesA.W., DimitrovN.V.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol, 15: 2483–2493, 1997.
66.
BearH.D., AndersonS., BrownA., SmithR., MamounasE.P., FisherB., MargoleseR., TheoretH., SoranA., WickerhamD.L., WolmarkN.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.J Clin Oncol, 21: 4165–4174, 2003.
